InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 09/23/22
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022GlobeNewsWire • 09/19/22
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica BusinessGlobeNewsWire • 09/08/22
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis BullosaGlobeNewsWire • 07/25/22
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin ConditionsGlobeNewsWire • 06/14/22
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness SectorGlobeNewsWire • 06/09/22
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 06/06/22
InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 05/13/22
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/13/22
InMed to Supply Rare Cannabinoids to Radicle Science's “Radicle Energy Study” to Assess the Health Effects of THCVGlobeNewsWire • 05/05/22
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research ExpertGlobeNewsWire • 04/28/22
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness SectorGlobeNewsWire • 04/21/22